Omeros Corporation

About Omeros Corporation

Omeros is a biopharmaceutical company focused on transforming patient care through next-generation therapeutics. They aim to deliver innovative, cutting-edge science and develop first-in-class drugs to address challenging diseases and significant unmet medical needs.

Products & Services

Narsoplimab (OMS721):A therapeutic drug in Omeros' pipeline targeting specific medical needs.

OMS405:A drug candidate in development within Omeros' pipeline.

Zaltenibart (OMS906):A drug candidate focused on addressing unmet medical needs.

MASP-2, MASP-3, MASP-2/-3:Therapeutics targeting specific protein pathways.

Adoptive T Cell Therapies / CAR T:Cellular therapies aimed at innovative treatment approaches.

GPCR Platform:A platform for developing drugs targeting G protein-coupled receptors.

Specialties

Innovative therapeutics First-in-class drugs Unmet medical needs Small-molecule and protein therapeutics Groundbreaking science

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 22000000 MR: - FA: $22 million FAN: 22000000	D: 2025-07-24 FD: 2025-07-24	1 investors
2	RT: Grant T: - FT: Grant	A: 4020000 MR: - FA: $4.02 million FAN: 4020000	D: 2025-03-13 FD: 2025-03-13	1 investors
3	RT: Debt T: - FT: Debt	A: 67100000 MR: - FA: $67.1 million FAN: 67100000	D: 2024-06-03 FD: 2024-06-03	2 investors
4	RT: Grant T: - FT: Grant	A: 6690000 MR: - FA: 6.69 million FAN: 6690000	D: 2023-04-07 FD: 2023-04-07	1 investors
5	RT: Milestone Payment T: - FT: Milestone Payment	A: 200000000 MR: - FA: $200 million FAN: 200000000	D: 2023-02-06 FD: 2023-02-06	1 investors

Registered Direct Offering Latest

2025-07-24

$22.0M

1 investor (Pro only)

Grant 2025-03-13

$4.0M

Debt 2024-06-03

$67.1M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Gregory A. Demopulos

Chairman and Chief Executive Officer

D

David J. Borges

Chief Accounting Officer

P

Peter B. Cancelmo

Vice President, General Counsel and Secretary

N

Nadia Dac

Chief Commercial Officer

M

Mariana N. Dimitrova

Vice President Chemistry, Manufacturing, and Controls

G

George A. Gaitanaris

Chief Scientific Officer

View 15 more team members with Pro

Unlock Full Team Directory

Recent News